Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
caffeine + omeprazole + flurbiprofen + dextromethorphan + midazolam
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Rectal, Intranasal, Intramuscular, Intravenous
01
Overview
A combination of five distinct drugs: caffeine (a stimulant), omeprazole (a proton pump inhibitor), flurbiprofen (a non-steroidal anti-inflammatory drug), dextromethorphan (a cough suppressant), and midazolam (a benzodiazepine). This combination is not a standard therapeutic regimen and would require careful medical supervision due to potential interactions between the components.
02
Targets
ADORA2A (Adenosine A₂A Receptor)BZD site (GABA-A receptor benzodiazepine site)ATP4A (Potassium–transporting ATPase alpha chain 1)SIGMAR1 (Sigma non-opioid intracellular receptor 1)SERT (Sodium-dependent serotonin transporter)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADORA1 (Adenosine receptor A1 subtype)N-methyl-D-aspartate receptor phencyclidine/channel site
Beyond the preview
Go deeper on caffeine + omeprazole + flurbiprofen + dextromethorphan + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on caffeine + omeprazole + flurbiprofen + dextromethorphan + midazolam.